KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Resmed (RMD) EBITDA Margin (2016 - 2025)

Resmed's EBITDA Margin history spans 17 years, with the latest figure at 34.56% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 201.0% year-over-year to 34.56%; the TTM value through Dec 2025 reached 33.7%, up 203.0%, while the annual FY2025 figure was 34.92%, 485.0% up from the prior year.
  • EBITDA Margin reached 34.56% in Q4 2025 per RMD's latest filing, up from 33.43% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 34.56% in Q4 2025 to a low of 23.66% in Q4 2023.
  • Average EBITDA Margin over 5 years is 29.36%, with a median of 28.99% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: crashed -345bps in 2023, then skyrocketed 889bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 27.79% in 2021, then decreased by -2bps to 27.1% in 2022, then fell by -13bps to 23.66% in 2023, then surged by 38bps to 32.54% in 2024, then grew by 6bps to 34.56% in 2025.
  • Per Business Quant, the three most recent readings for RMD's EBITDA Margin are 34.56% (Q4 2025), 33.43% (Q3 2025), and 33.72% (Q2 2025).